Linagliptin

Navê Kîmyayî:

8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dion

Koda SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Koda InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34) 15-20-27-16 (2) 18-10-6-7-11-19 (18) 28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Bişkojka InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Keyword:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Çareserî:Di DMSO de çareser dibe

Embarkirinî:0 - 4 ° C ji bo demek kurt (roj heta hefte), an -20 ° C ji bo demek dirêj (mehan).

Terîf:

Linagliptin, ku wekî BI-1356 jî tê zanîn, astengkerek DPP-4 e ku ji hêla Boehringer Ingelheim ve hatî pêşve xistin ji bo dermankirina şekirê şekir II. Linagliptin (rojane carekê) ji hêla FDA ya Dewletên Yekbûyî ve di 2-ê Gulana 2011-an de ji bo dermankirina şekirê tip II hate pejirandin. Ew ji hêla Boehringer Ingelheim û Lilly ve tê firotin.

Armanc: DPP-4